Use of androgen deprivation therapy with radiotherapy for intermediate- and high-risk prostate cancer across the United States
A partir des données du registre américain des cancers portant sur 95 941 patients atteints d'un cancer de la prostate à risque intermédiaire ou élevé de récidive, cet article analyse l'utilisation de l'hormonothérapie anti-androgénique en combinaison avec une radiothérapie
For aggressive, localized prostate cancer, the combination of androgen deprivation therapy (ADT) with radiotherapy (RT) is one of the best-studied treatments. Multiple randomized clinical trials have consistently demonstrated that adding ADT to RT improves survival.1- 5 Despite this large amount of level 1 evidence, controversy remains regarding the role of ADT. There are concerns that ADT may not benefit (or may even harm) patients with comorbidities and that the survival benefit from ADT may be replaced by dose-escalated RT, even though the latter has never been shown to improve survival. Therefore, we examined the adoption of ADT vs dose-escalated RT across the United States.